Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-08-21

AUTHORS

Howard L. Kaufman, Lawrence H. Schwartz, William N. William, Mario Sznol, Kyle Fahrbach, Yingxin Xu, Eric Masson, Andrea Vergara-Silva

ABSTRACT

PurposeClassical clinical endpoints [e.g., objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS)] may not be appropriate for immune checkpoint blockers (ICBs). We evaluated correlations between these endpoints and overall survival (OS) for surrogacy.MethodsRandomized controlled trials (RCTs) of solid tumors patients treated with ICBs published between 01/2005 and 03/2017, and congress proceedings (2014–2016) were included. Arm-level analyses measured 6-month PFS rate to predict 18-month OS rate. Comparison-level analyses measured ORR odds ratio (OR), DCR OR, and 6-month PFS hazard ratio (HR) to predict OS HR. A pooled analysis for single-agent ICBs and ICBs plus chemotherapy vs chemotherapy was conducted. Studies of single-agent ICBs vs chemotherapy were separately analyzed.Results27 RCTs involving 61 treatment arms and 10,300 patients were included. Arm-level analysis showed higher 6- or 9-month PFS rates predicted better 18-month OS rates for ICB arms and/or chemotherapy arms. ICB arms had a higher average OS rate vs chemotherapy for all PFS rates. Comparison-level analysis showed a nonsignificant/weak correlation between ORR OR (adjusted R2 = − 0.069; P = 0.866) or DCR OR (adjusted R2 = 0.271; P = 0.107) and OS HR. PFS HR correlated weakly with OS HR in the pooled (adjusted R2 = 0.366; P = 0.005) and single-agent (adjusted R2 = 0.452; P = 0.005) ICB studies. Six-month PFS HR was highly predictive of OS HR for single-agent ICBs (adjusted R2 = 0.907; P < 0.001), but weakly predictive in the pooled analysis (adjusted R2 = 0.333; P = 0.023).ConclusionsPFS was an imperfect surrogate for OS. Predictive value of 6-month PFS HR for OS HR in the single-agent ICB analysis requires further exploration. More... »

PAGES

2245-2261

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-018-2738-x

DOI

http://dx.doi.org/10.1007/s00432-018-2738-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106281720

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30132118


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endpoint Determination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Replimune Inc., 18 Commerce Way, 01801, Woburn, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Massachusetts General Hospital, 55 Fruit St Gray 730, Boston, MA, USA", 
            "Replimune Inc., 18 Commerce Way, 01801, Woburn, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaufman", 
        "givenName": "Howard L.", 
        "id": "sg:person.01333264012.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333264012.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, 622 W 168th St, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.21729.3f", 
          "name": [
            "Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, 622 W 168th St, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "Lawrence H.", 
        "id": "sg:person.011027760412.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011027760412.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro Oncol\u00f3gico BP, a Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil", 
          "id": "http://www.grid.ac/institutes/grid.414374.1", 
          "name": [
            "MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA", 
            "Centro Oncol\u00f3gico BP, a Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "William", 
        "givenName": "William N.", 
        "id": "sg:person.01262777171.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262777171.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale School of Medicine, 333 Cedar St, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale School of Medicine, 333 Cedar St, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.423257.5", 
          "name": [
            "Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fahrbach", 
        "givenName": "Kyle", 
        "id": "sg:person.01172723623.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172723623.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.418961.3", 
          "name": [
            "Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA", 
            "Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Yingxin", 
        "id": "sg:person.0740106667.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740106667.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biogen, 225 Binney St, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417832.b", 
          "name": [
            "AstraZeneca, 35 Gatehouse Dr, Waltham, MA, USA", 
            "Biogen, 225 Binney St, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masson", 
        "givenName": "Eric", 
        "id": "sg:person.014363567577.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ayala Pharmaceuticals, 1313 N. Market Str, Suite 5100, Wilmington, DE, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA", 
            "Ayala Pharmaceuticals, 1313 N. Market Str, Suite 5100, Wilmington, DE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vergara-Silva", 
        "givenName": "Andrea", 
        "id": "sg:person.011534576530.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011534576530.49"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2288-11-139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037378478", 
          "https://doi.org/10.1186/1471-2288-11-139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1479-5876-9-204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002969174", 
          "https://doi.org/10.1186/1479-5876-9-204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-017-0276-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091624031", 
          "https://doi.org/10.1186/s40425-017-0276-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-009-9376-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021055401", 
          "https://doi.org/10.1007/s10637-009-9376-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12916-017-0902-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090559553", 
          "https://doi.org/10.1186/s12916-017-0902-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-12-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010370832", 
          "https://doi.org/10.1186/1471-2288-12-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-08-21", 
    "datePublishedReg": "2018-08-21", 
    "description": "PurposeClassical clinical endpoints [e.g., objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS)] may not be appropriate for immune checkpoint blockers (ICBs). We evaluated correlations between these endpoints and overall survival (OS) for surrogacy.MethodsRandomized controlled trials (RCTs) of solid tumors patients treated with ICBs published between 01/2005 and 03/2017, and congress proceedings (2014\u20132016) were included. Arm-level analyses measured 6-month PFS rate to predict 18-month OS rate. Comparison-level analyses measured ORR odds ratio (OR), DCR OR, and 6-month PFS hazard ratio (HR) to predict OS HR. A pooled analysis for single-agent ICBs and ICBs plus chemotherapy vs chemotherapy was conducted. Studies of single-agent ICBs vs chemotherapy were separately analyzed.Results27 RCTs involving 61 treatment arms and 10,300 patients were included. Arm-level analysis showed higher 6- or 9-month PFS rates predicted better 18-month OS rates for ICB arms and/or chemotherapy arms. ICB arms had a higher average OS rate vs chemotherapy for all PFS rates. Comparison-level analysis showed a nonsignificant/weak correlation between ORR OR (adjusted R2\u2009=\u2009\u2212\u20090.069; P\u2009=\u20090.866) or DCR OR (adjusted R2\u2009=\u20090.271; P\u2009=\u20090.107) and OS HR. PFS HR correlated weakly with OS HR in the pooled (adjusted R2\u2009=\u20090.366; P\u2009=\u20090.005) and single-agent (adjusted R2\u2009=\u20090.452; P\u2009=\u20090.005) ICB studies. Six-month PFS HR was highly predictive of OS HR for single-agent ICBs (adjusted R2\u2009=\u20090.907; P\u2009<\u20090.001), but weakly predictive in the pooled analysis (adjusted R2\u2009=\u20090.333; P\u2009=\u20090.023).ConclusionsPFS was an imperfect surrogate for OS. Predictive value of 6-month PFS HR for OS HR in the single-agent ICB analysis requires further exploration.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00432-018-2738-x", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "144"
      }
    ], 
    "keywords": [
      "immune checkpoint blockers", 
      "OS hazard ratio", 
      "PFS hazard ratio", 
      "hazard ratio", 
      "overall survival", 
      "PFS rates", 
      "OS rates", 
      "checkpoint blockers", 
      "pooled analysis", 
      "clinical endpoints", 
      "solid tumor patients", 
      "chemotherapy arm", 
      "treatment arms", 
      "tumor patients", 
      "odds ratio", 
      "predictive value", 
      "chemotherapy", 
      "systematic review", 
      "imperfect surrogate", 
      "patients", 
      "endpoint", 
      "blockers", 
      "congress proceedings", 
      "survival", 
      "arm", 
      "weak correlation", 
      "further exploration", 
      "DCR", 
      "ConclusionsPFS", 
      "MethodsRandomized", 
      "RCTs", 
      "trials", 
      "rate", 
      "study", 
      "surrogate", 
      "correlation", 
      "review", 
      "analysis", 
      "evaluation", 
      "ratio", 
      "surrogacy", 
      "values", 
      "proceedings", 
      "ORR", 
      "exploration"
    ], 
    "name": "Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis", 
    "pagination": "2245-2261", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106281720"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-018-2738-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30132118"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-018-2738-x", 
      "https://app.dimensions.ai/details/publication/pub.1106281720"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_776.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00432-018-2738-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2738-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2738-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2738-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2738-x'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      83 URIs      69 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-018-2738-x schema:about N2d48648eba2b4eeebc93ff5c13e5a485
2 N375533e7d9b44a3da2a81c7679384f53
3 N49010bfcf51d4072bfabaf60403ac5a0
4 N7ecd9055570e4129b6095cfefff69002
5 N9ca9b369c434415c8dbd515e9471f330
6 Na8f4e09d443441199fa61af411e1d023
7 Nae93673239d94630a8b0bea0d8523c00
8 anzsrc-for:11
9 anzsrc-for:1112
10 schema:author N201bda8eb7c141eea01d025fb921f2f3
11 schema:citation sg:pub.10.1007/s10637-009-9376-8
12 sg:pub.10.1186/1471-2288-11-139
13 sg:pub.10.1186/1471-2288-12-9
14 sg:pub.10.1186/1479-5876-9-204
15 sg:pub.10.1186/s12916-017-0902-9
16 sg:pub.10.1186/s40425-017-0276-8
17 schema:datePublished 2018-08-21
18 schema:datePublishedReg 2018-08-21
19 schema:description PurposeClassical clinical endpoints [e.g., objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS)] may not be appropriate for immune checkpoint blockers (ICBs). We evaluated correlations between these endpoints and overall survival (OS) for surrogacy.MethodsRandomized controlled trials (RCTs) of solid tumors patients treated with ICBs published between 01/2005 and 03/2017, and congress proceedings (2014–2016) were included. Arm-level analyses measured 6-month PFS rate to predict 18-month OS rate. Comparison-level analyses measured ORR odds ratio (OR), DCR OR, and 6-month PFS hazard ratio (HR) to predict OS HR. A pooled analysis for single-agent ICBs and ICBs plus chemotherapy vs chemotherapy was conducted. Studies of single-agent ICBs vs chemotherapy were separately analyzed.Results27 RCTs involving 61 treatment arms and 10,300 patients were included. Arm-level analysis showed higher 6- or 9-month PFS rates predicted better 18-month OS rates for ICB arms and/or chemotherapy arms. ICB arms had a higher average OS rate vs chemotherapy for all PFS rates. Comparison-level analysis showed a nonsignificant/weak correlation between ORR OR (adjusted R2 = − 0.069; P = 0.866) or DCR OR (adjusted R2 = 0.271; P = 0.107) and OS HR. PFS HR correlated weakly with OS HR in the pooled (adjusted R2 = 0.366; P = 0.005) and single-agent (adjusted R2 = 0.452; P = 0.005) ICB studies. Six-month PFS HR was highly predictive of OS HR for single-agent ICBs (adjusted R2 = 0.907; P < 0.001), but weakly predictive in the pooled analysis (adjusted R2 = 0.333; P = 0.023).ConclusionsPFS was an imperfect surrogate for OS. Predictive value of 6-month PFS HR for OS HR in the single-agent ICB analysis requires further exploration.
20 schema:genre article
21 schema:isAccessibleForFree true
22 schema:isPartOf N24a85d90348f449d9b4d232eb8970189
23 Nabf5f8c6fd354c109978722dec9eadfb
24 sg:journal.1313647
25 schema:keywords ConclusionsPFS
26 DCR
27 MethodsRandomized
28 ORR
29 OS hazard ratio
30 OS rates
31 PFS hazard ratio
32 PFS rates
33 RCTs
34 analysis
35 arm
36 blockers
37 checkpoint blockers
38 chemotherapy
39 chemotherapy arm
40 clinical endpoints
41 congress proceedings
42 correlation
43 endpoint
44 evaluation
45 exploration
46 further exploration
47 hazard ratio
48 immune checkpoint blockers
49 imperfect surrogate
50 odds ratio
51 overall survival
52 patients
53 pooled analysis
54 predictive value
55 proceedings
56 rate
57 ratio
58 review
59 solid tumor patients
60 study
61 surrogacy
62 surrogate
63 survival
64 systematic review
65 treatment arms
66 trials
67 tumor patients
68 values
69 weak correlation
70 schema:name Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
71 schema:pagination 2245-2261
72 schema:productId N3138229dfe2646849030843a4b9de186
73 N3f8faa88120a42569351d40a2a010fcd
74 Nbf703d391b1c4fca8045acc3ea385233
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106281720
76 https://doi.org/10.1007/s00432-018-2738-x
77 schema:sdDatePublished 2022-09-02T16:01
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher Neaae59e23bec4acbbaf48663ec08d1bf
80 schema:url https://doi.org/10.1007/s00432-018-2738-x
81 sgo:license sg:explorer/license/
82 sgo:sdDataset articles
83 rdf:type schema:ScholarlyArticle
84 N1554a390680949fb87b842e60fc58bbb rdf:first sg:person.01172723623.69
85 rdf:rest N88b521c21d37442daab3b6fd4917a0c4
86 N201bda8eb7c141eea01d025fb921f2f3 rdf:first sg:person.01333264012.85
87 rdf:rest N58263ea973c545e0812e58fdbb2d6383
88 N24a85d90348f449d9b4d232eb8970189 schema:volumeNumber 144
89 rdf:type schema:PublicationVolume
90 N2d48648eba2b4eeebc93ff5c13e5a485 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Randomized Controlled Trials as Topic
92 rdf:type schema:DefinedTerm
93 N3138229dfe2646849030843a4b9de186 schema:name dimensions_id
94 schema:value pub.1106281720
95 rdf:type schema:PropertyValue
96 N375533e7d9b44a3da2a81c7679384f53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Neoplasms
98 rdf:type schema:DefinedTerm
99 N3f8faa88120a42569351d40a2a010fcd schema:name doi
100 schema:value 10.1007/s00432-018-2738-x
101 rdf:type schema:PropertyValue
102 N49010bfcf51d4072bfabaf60403ac5a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Humans
104 rdf:type schema:DefinedTerm
105 N58263ea973c545e0812e58fdbb2d6383 rdf:first sg:person.011027760412.07
106 rdf:rest Nc58ce379be0f48da9985ca976bc9e6de
107 N7ecd9055570e4129b6095cfefff69002 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Survival Analysis
109 rdf:type schema:DefinedTerm
110 N88b521c21d37442daab3b6fd4917a0c4 rdf:first sg:person.0740106667.02
111 rdf:rest Nb6a9f7ae9b864606a6ef833ffed30399
112 N9ca9b369c434415c8dbd515e9471f330 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Molecular Targeted Therapy
114 rdf:type schema:DefinedTerm
115 Na8f4e09d443441199fa61af411e1d023 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antineoplastic Agents
117 rdf:type schema:DefinedTerm
118 Nabf5f8c6fd354c109978722dec9eadfb schema:issueNumber 11
119 rdf:type schema:PublicationIssue
120 Nae93673239d94630a8b0bea0d8523c00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Endpoint Determination
122 rdf:type schema:DefinedTerm
123 Nb6a9f7ae9b864606a6ef833ffed30399 rdf:first sg:person.014363567577.38
124 rdf:rest Nf9abb1335adf4bb3a4d02210ba7b8f13
125 Nbf703d391b1c4fca8045acc3ea385233 schema:name pubmed_id
126 schema:value 30132118
127 rdf:type schema:PropertyValue
128 Nc58ce379be0f48da9985ca976bc9e6de rdf:first sg:person.01262777171.70
129 rdf:rest Nd1c9a754bd444796b7d92a963ef93a47
130 Nd1c9a754bd444796b7d92a963ef93a47 rdf:first sg:person.0706626451.72
131 rdf:rest N1554a390680949fb87b842e60fc58bbb
132 Neaae59e23bec4acbbaf48663ec08d1bf schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 Nf9abb1335adf4bb3a4d02210ba7b8f13 rdf:first sg:person.011534576530.49
135 rdf:rest rdf:nil
136 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
137 schema:name Medical and Health Sciences
138 rdf:type schema:DefinedTerm
139 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
140 schema:name Oncology and Carcinogenesis
141 rdf:type schema:DefinedTerm
142 sg:journal.1313647 schema:issn 0171-5216
143 1432-1335
144 schema:name Journal of Cancer Research and Clinical Oncology
145 schema:publisher Springer Nature
146 rdf:type schema:Periodical
147 sg:person.011027760412.07 schema:affiliation grid-institutes:grid.21729.3f
148 schema:familyName Schwartz
149 schema:givenName Lawrence H.
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011027760412.07
151 rdf:type schema:Person
152 sg:person.011534576530.49 schema:affiliation grid-institutes:None
153 schema:familyName Vergara-Silva
154 schema:givenName Andrea
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011534576530.49
156 rdf:type schema:Person
157 sg:person.01172723623.69 schema:affiliation grid-institutes:grid.423257.5
158 schema:familyName Fahrbach
159 schema:givenName Kyle
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172723623.69
161 rdf:type schema:Person
162 sg:person.01262777171.70 schema:affiliation grid-institutes:grid.414374.1
163 schema:familyName William
164 schema:givenName William N.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262777171.70
166 rdf:type schema:Person
167 sg:person.01333264012.85 schema:affiliation grid-institutes:None
168 schema:familyName Kaufman
169 schema:givenName Howard L.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333264012.85
171 rdf:type schema:Person
172 sg:person.014363567577.38 schema:affiliation grid-institutes:grid.417832.b
173 schema:familyName Masson
174 schema:givenName Eric
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38
176 rdf:type schema:Person
177 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.47100.32
178 schema:familyName Sznol
179 schema:givenName Mario
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
181 rdf:type schema:Person
182 sg:person.0740106667.02 schema:affiliation grid-institutes:grid.418961.3
183 schema:familyName Xu
184 schema:givenName Yingxin
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740106667.02
186 rdf:type schema:Person
187 sg:pub.10.1007/s10637-009-9376-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021055401
188 https://doi.org/10.1007/s10637-009-9376-8
189 rdf:type schema:CreativeWork
190 sg:pub.10.1186/1471-2288-11-139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037378478
191 https://doi.org/10.1186/1471-2288-11-139
192 rdf:type schema:CreativeWork
193 sg:pub.10.1186/1471-2288-12-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010370832
194 https://doi.org/10.1186/1471-2288-12-9
195 rdf:type schema:CreativeWork
196 sg:pub.10.1186/1479-5876-9-204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002969174
197 https://doi.org/10.1186/1479-5876-9-204
198 rdf:type schema:CreativeWork
199 sg:pub.10.1186/s12916-017-0902-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090559553
200 https://doi.org/10.1186/s12916-017-0902-9
201 rdf:type schema:CreativeWork
202 sg:pub.10.1186/s40425-017-0276-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091624031
203 https://doi.org/10.1186/s40425-017-0276-8
204 rdf:type schema:CreativeWork
205 grid-institutes:None schema:alternateName Ayala Pharmaceuticals, 1313 N. Market Str, Suite 5100, Wilmington, DE, USA
206 Replimune Inc., 18 Commerce Way, 01801, Woburn, MA, USA
207 schema:name AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA
208 Ayala Pharmaceuticals, 1313 N. Market Str, Suite 5100, Wilmington, DE, USA
209 Massachusetts General Hospital, 55 Fruit St Gray 730, Boston, MA, USA
210 Replimune Inc., 18 Commerce Way, 01801, Woburn, MA, USA
211 rdf:type schema:Organization
212 grid-institutes:grid.21729.3f schema:alternateName Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, 622 W 168th St, New York, NY, USA
213 schema:name Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital, 622 W 168th St, New York, NY, USA
214 rdf:type schema:Organization
215 grid-institutes:grid.414374.1 schema:alternateName Centro Oncológico BP, a Beneficência Portuguesa de São Paulo, São Paulo, Brazil
216 schema:name Centro Oncológico BP, a Beneficência Portuguesa de São Paulo, São Paulo, Brazil
217 MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
218 rdf:type schema:Organization
219 grid-institutes:grid.417832.b schema:alternateName Biogen, 225 Binney St, Cambridge, MA, USA
220 schema:name AstraZeneca, 35 Gatehouse Dr, Waltham, MA, USA
221 Biogen, 225 Binney St, Cambridge, MA, USA
222 rdf:type schema:Organization
223 grid-institutes:grid.418961.3 schema:alternateName Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, USA
224 schema:name Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA
225 Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, USA
226 rdf:type schema:Organization
227 grid-institutes:grid.423257.5 schema:alternateName Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA
228 schema:name Evidera, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA
229 rdf:type schema:Organization
230 grid-institutes:grid.47100.32 schema:alternateName Yale School of Medicine, 333 Cedar St, New Haven, CT, USA
231 schema:name Yale School of Medicine, 333 Cedar St, New Haven, CT, USA
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...